Pharma Focus Asia

Eli Lilly and Company Launched New Rapid Acting Insulin Lyumjev™

Lyumjev™, a new and innovative rapid acting insulin ranging from 100 units/mL and 200 units/mL was launched by Eli Lilly and Company to enhance glycemic control in diabetic patients of type 1 & 2.

Lyumjev is a novel formulation of insulin lispro, designed to speed the absorption of insulin into the blood stream and reduce A1C levels. This new rapid-acting insulin, Lyumjev manages the blood sugar levels in diabetic adult patients after meals similar to the working of natural working of insulin after meals in people without diabetes.

With the new technological advancements made in glucose monitoring, patients can now easily see the blood glucose spikes that happen naturally after a meal. Lyumjev™, serves as a new treatment option for patients with diabetes to help them control post-meal blood sugar levels.

Lyumjev™, fast acting insulin was approved by US Food and Drug Administration (FDA) based on the Phase 3 studies PRONTO-T1D and PRONTO-T2D,which were randomised, active controlled, treat-to-target comparisons of Lyumjev and Humalog® (insulin lispro injection, 100 units/mL) in adults with type 1 and type 2 diabetes, respectively.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference